BioCurex Presents RECAF Blood Test Results at National Cancer Institute Workshop.Business Editors/Health/Medical Writers 3rd Annual EDRN EDRN Early Detection Research Network Scientific Workshop RICHMOND, British Columbia--(BUSINESS WIRE)--June 9, 2004 BioCurex Inc. (Pink Sheets:BOCX) is pleased to announce that it will be presenting four communications on its blood test for cancer detection at the 3rd Annual Early Detection Research Network (EDRN) Scientific Workshop to be held June 14-16 in Bethesda, Maryland. The EDRN is an initiative of National Cancer Institute's Division of Cancer Prevention. Its objectives are: -- Development and testing of promising biomarkers or technologies -- Evaluation of promising, analytically proven biomarkers or technologies -- Collaboration among academic and industrial leaders in molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller , molecular genetics molecular genetics n. The branch of genetics that deals with hereditary transmission and variation on the molecular level. , clinical oncology, computer science, public health and clinical application for early cancer detection -- Expand public-private partnership for validation studies by providing access to EDRN resources BioCurex will be presenting results obtained with its Serum-RECAF(TM) tests on Breast, Stomach, Ovarian and Lung cancers. The detection sensitivity in these cancers is approximately 90% with 95% specificity. Dr. Moro commented: "Presenting our results at this meeting is important for BioCurex because of the resulting exposure to a large number of possible collaborations in the USA. The main purpose of the EDRN - a network of scientists, institutes and companies - is to generate such collaborations, which in turn result in access to samples, validation by American institutions and contacts with major companies in cancer diagnosis. A large variety of cancer samples is critical to the determination of how early we can detect cancer. This presentation will move us towards additional validation by institutions associated with the US National Cancer Institute. We anticipate that our results, which demonstrate that we can use a drop of blood to detect cancer in 90% of cancer patients, will attract the attention of the participants." The EDRN Biomarkers Development Labs include: Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. University of Texas MD Anderson University Maryland University of Colorado University of Colorado may refer to:
Yale University Northwestern University Medical Center Moffitt Cancer Center, University of South Florida • • [ University of Michigan (body, education) University of Michigan - A large cosmopolitan university in the Midwest USA. Over 50000 students are enrolled at the University of Michigan's three campuses. The students come from 50 states and over 100 foreign countries. University of Texas Southwestern Genetica, Inc. Duke University Thomas Jefferson University It began as Jefferson Medical College in 1824. On July 1, 1969 the institution officially became Thomas Jefferson University. The university is made up of three colleges:
University of Pittsburgh Eastern Virginia Medical School Eastern Virginia Medical School, in Norfolk, Virginia is a public medical school. University of Washington, Seattle About BioCurex: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technologies in the area of cancer diagnosis. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. Our blood test for cancer known as Serum-RECAF(TM) has not yet been approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and it is to be used for research purposes only. To find out more about BioCurex (BOCX), visit our website at www.biocurex.com. Note: The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion